AQST

SEC source: 0001214659-23-003690 · marketforms-59525.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,761

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-23-003689 · marketforms-59532.xml · nonDerivative · entry 1

Wargacki Stephen · CIK 0001960165 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,956

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-013279 · marketforms-57373.xml · derivative · entry 1

Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-013278 · marketforms-57374.xml · derivative · entry 1

TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-013282 · marketforms-57370.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-013281 · marketforms-57371.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-013280 · marketforms-57372.xml · derivative · entry 1

Marshall Ken W. · CIK 0001740092 · SVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-010993 · marketforms-57083.xml · derivative · entry 1

Truitt Kenneth · CIK 0001946056 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-09-06

F1 · derivative.exercise_date: Granted as an inducement equity award under the Aquestive Therapeutics, Inc. 2022 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5636(c)(4). The options will vest annually 25% on the first and second anniversaries of the Grant Date and 50% on the third anniversary of the Grant Date, subject to Dr. Truitt's continued employment through the applicable vesting date.

SEC source: 0001214659-22-010328 · marketforms-56912.xml · derivative · entry 1

MORRIS TIMOTHY E · CIK 0001191286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2032-08-16

F1 · derivative.exercise_date: Granted under the Company's 2018 Equity Incentive Plan, which meets the requirements of Rule 16b-3. The options will vest in three annual installments with 1/3% on the 1st installment, 1/3% on the 2nd installment and 1/3% on the 3rd installment.

SEC source: 0001214659-22-009753 · marketforms-56662.xml · derivative · entry 1

Barber Daniel · CIK 0001742266 · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-08-05

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-008286 · marketforms-56516.xml · derivative · entry 2

COSTA SANTO J · CIK 0001013419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Mr. Costa's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-22-008288 · marketforms-56517.xml · derivative · entry 1

Krop Julie · CIK 0001643127 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-22-008289 · marketforms-56518.xml · derivative · entry 1

Taglietti Marco · CIK 0001408870 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Taglietti's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-22-008294 · marketforms-56515.xml · derivative · entry 2

Cochran John · CIK 0001406773 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-22-008292 · marketforms-56514.xml · derivative · entry 2

BROWN GREGORY B · CIK 0001373585 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001628280-22-017186 · wf-form4_165530302948520.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,532

F1 · price: This transaction was executed in multiple transactions at the price of $0.81. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and price at which the transaction was effected.

SEC source: 0001628280-22-016875 · wf-form4_165489638239475.xml · derivative · entry 2

Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,871

Underlying: Common Stock · 45,871 shares

Expires 2027-06-08

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

SEC source: 0001628280-22-016875 · wf-form4_165489638239475.xml · nonDerivative · entry 1

Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 882,871

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

SEC source: 0001628280-22-016876 · wf-form4_165489641133153.xml · derivative · entry 2

Barber Daniel · CIK 0001742266 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,743

Underlying: Common Stock · 91,743 shares

Expires 2027-06-08

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

SEC source: 0001628280-22-016876 · wf-form4_165489641133153.xml · nonDerivative · entry 1

Barber Daniel · CIK 0001742266 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,702

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

SEC source: 0001628280-22-016872 · wf-form4_165489636547699.xml · derivative · entry 2

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,293

Underlying: Common Stock · 2,293 shares

Expires 2027-06-08

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13

SEC source: 0001628280-22-016872 · wf-form4_165489636547699.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,532

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13

SEC source: 0001628280-22-016871 · wf-form4_165489634971386.xml · derivative · entry 2

BRAENDER LORI J · CIK 0001752955 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,761

Underlying: Common Stock · 13,761 shares

Expires 2027-06-08

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

SEC source: 0001628280-22-016871 · wf-form4_165489634971386.xml · nonDerivative · entry 1

BRAENDER LORI J · CIK 0001752955 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,761

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.

SEC source: 0001214659-22-003898 · marketforms-55764.xml · derivative · entry 1

Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003894 · marketforms-55758.xml · derivative · entry 1

Kendall Keith J · CIK 0001406834 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,000

Underlying: Common Stock · 375,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003899 · marketforms-55765.xml · derivative · entry 1

TOTH A ERNEST JR · CIK 0001280273 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003901 · marketforms-55760.xml · derivative · entry 1

Barber Daniel · CIK 0001742266 · SVP-Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003900 · marketforms-55767.xml · derivative · entry 1

Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003896 · marketforms-55762.xml · derivative · entry 1

BRAENDER LORI J · CIK 0001752955 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003897 · marketforms-55763.xml · derivative · entry 1

Marshall Ken W. · CIK 0001740092 · SVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-22-003895 · marketforms-55761.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

SEC source: 0001214659-21-009051 · marketforms-53684.xml · nonDerivative · entry 2

Kendall Keith J · CIK 0001406834 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · Custodian of UTMA account for Anna Kendall

Disclosed balance after: 1,000

F1 · kind: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild.

F1 · shares: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild.

F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts.

SEC source: 0001214659-21-009051 · marketforms-53684.xml · nonDerivative · entry 1

Kendall Keith J · CIK 0001406834 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 636,149

F1 · kind: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild.

F1 · shares: On August 26, 2021, the reporting person gifted these shares to a Uniform Gift to Minors Act custodial account for the benefit of the reporting person's grandchild Anna Kendall, for no consideration and for which the reporting person is the custodian. The reporting person may be deemed to have acquired indirect beneficial ownership of such shares upon gifting them to the custodial account. The reporting person disclaims beneficial ownership of the shares held by his grandchild.

F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts.

SEC source: 0001214659-21-006714 · marketforms-53148.xml · derivative · entry 2

COSTA SANTO J · CIK 0001013419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Mr. Costa's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006716 · marketforms-53149.xml · derivative · entry 1

Krop Julie · CIK 0001643127 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006717 · marketforms-53150.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006720 · marketforms-53153.xml · derivative · entry 1

Taglietti Marco · CIK 0001408870 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Dr. Taglietti's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006719 · marketforms-53147.xml · derivative · entry 2

Cochran John · CIK 0001406773 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006718 · marketforms-53154.xml · derivative · entry 1

TOTH A ERNEST JR · CIK 0001280273 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option to purchase Common Stock of the Issuer under the Issuer's 2018 Equity Incentive Plan (the "Plan"). Said options vest over a three-year period, with 25% of such option vesting on each of the one-year and two-year anniversaries of the option vesting commencement date and the remaining 50% vesting on the third-year anniversary of the option vesting commencement date, provided that at the relevant vesting date, the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. The option expires ten years after the date of grant.

SEC source: 0001214659-21-006715 · marketforms-53151.xml · derivative · entry 2

Scibetta James S · CIK 0001383242 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Mr. Scibetta's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006757 · marketforms-53152.xml · derivative · entry 2

BROWN GREGORY B · CIK 0001373585 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date.

SEC source: 0001214659-21-006162 · marketforms-52778.xml · nonDerivative · entry 1

Cochran John · CIK 0001406773 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,486

F1 · kind: The reporting person gifted these shares of Common Stock to Event Facilities Fort Worth Inc. for no consideration.

F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts.

SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 6

BRATTON DOUGLAS K · CIK 0001281933 · 10% owner

MonoLine Partners, L.P. · CIK 0001747211 · 10% owner

MonoLine RX, L.P. · CIK 0001410626 · 10% owner

MonoLine RX II, L.P. · CIK 0001410625 · 10% owner

MonoLine RX III, L.P. · CIK 0001747169 · 10% owner

MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner

MRX Partners, LLC · CIK 0001746904 · 10% owner

Bratton Capital Inc. · CIK 0001723783 · 10% owner

Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,948,578

F9 · kind: Shares of Common Stock acquired through pro rata distribution for no consideration by MRX Partners.

F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F10 · ownership.nature: These securities are beneficially owned by MonoLine.

SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 5

BRATTON DOUGLAS K · CIK 0001281933 · 10% owner

MonoLine Partners, L.P. · CIK 0001747211 · 10% owner

MonoLine RX, L.P. · CIK 0001410626 · 10% owner

MonoLine RX II, L.P. · CIK 0001410625 · 10% owner

MonoLine RX III, L.P. · CIK 0001747169 · 10% owner

MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner

MRX Partners, LLC · CIK 0001746904 · 10% owner

Bratton Capital Inc. · CIK 0001723783 · 10% owner

Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F8 · ownership.nature: These securities are beneficially owned by MRX Partners.

SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 4

BRATTON DOUGLAS K · CIK 0001281933 · 10% owner

MonoLine Partners, L.P. · CIK 0001747211 · 10% owner

MonoLine RX, L.P. · CIK 0001410626 · 10% owner

MonoLine RX II, L.P. · CIK 0001410625 · 10% owner

MonoLine RX III, L.P. · CIK 0001747169 · 10% owner

MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner

MRX Partners, LLC · CIK 0001746904 · 10% owner

Bratton Capital Inc. · CIK 0001723783 · 10% owner

Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 47,051

F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F7 · ownership.nature: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol.

SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 3

BRATTON DOUGLAS K · CIK 0001281933 · 10% owner

MonoLine Partners, L.P. · CIK 0001747211 · 10% owner

MonoLine RX, L.P. · CIK 0001410626 · 10% owner

MonoLine RX II, L.P. · CIK 0001410625 · 10% owner

MonoLine RX III, L.P. · CIK 0001747169 · 10% owner

MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner

MRX Partners, LLC · CIK 0001746904 · 10% owner

Bratton Capital Inc. · CIK 0001723783 · 10% owner

Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,657,943

F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F6 · ownership.nature: These securities are beneficially owned by Monoline III.

SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 2

BRATTON DOUGLAS K · CIK 0001281933 · 10% owner

MonoLine Partners, L.P. · CIK 0001747211 · 10% owner

MonoLine RX, L.P. · CIK 0001410626 · 10% owner

MonoLine RX II, L.P. · CIK 0001410625 · 10% owner

MonoLine RX III, L.P. · CIK 0001747169 · 10% owner

MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner

MRX Partners, LLC · CIK 0001746904 · 10% owner

Bratton Capital Inc. · CIK 0001723783 · 10% owner

Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,468,747

F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F5 · ownership.nature: These securities are beneficially owned by Monoline II.

SEC source: 0001214659-21-003203 · marketforms-51911.xml · nonDerivative · entry 1

BRATTON DOUGLAS K · CIK 0001281933 · 10% owner

MonoLine Partners, L.P. · CIK 0001747211 · 10% owner

MonoLine RX, L.P. · CIK 0001410626 · 10% owner

MonoLine RX II, L.P. · CIK 0001410625 · 10% owner

MonoLine RX III, L.P. · CIK 0001747169 · 10% owner

MonoSol Rx Genpar, L.P. · CIK 0001747548 · 10% owner

MRX Partners, LLC · CIK 0001746904 · 10% owner

Bratton Capital Inc. · CIK 0001723783 · 10% owner

Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,688,639

F1 · kind: Pro rata distribution for no consideration of shares of common stock of the Issuer ("Common Stock") by the applicable MonoLine Entity or Monosol (each as defined below), as indicated in the respective footnotes.

F2 · ownership.nature: These securities are owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the manager of MRX Partners and general partner of each of the other Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3 · ownership.nature: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F4 · ownership.nature: These securities are beneficially owned by Monoline Rx.

SEC source: 0001214659-21-003204 · marketforms-51914.xml · nonDerivative · entry 4

Cochran John · CIK 0001406773 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,986

F1 · kind: Pro rata distributions for no consideration of shares of common stock of the Issuer by the following entities, respectively (collectively, the "Distributing Entities"): MonoLine Rx, L.P., MonoLine Rx III, L.P., MonoSol Rx Genpar, L.P., and MRX Partners, LLC. The Reporting Person under this Form 4 possesses no voting or investment control over the securities held by the Distributing Entities.